Active monitoring for low-risk DCIS results in similar quality of life as standard treatment

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

Clinicians Star in Off-Broadway Musical About Antimicrobial Resistance

It’s not every day that working scientists and healthcare professionals sing alongside seasoned actors in a show, let alone in a musical about a pressing

September 7, 2024

The only tribal medical school in the U.S. graduates its first Native American doctors

There are so few Indigenous physicians in the United States — just 0.3% of doctors — that their numbers barely show up in charts and

May 16, 2024

Vanda Pharmaceuticals has another suitor

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Well, this wraps up

June 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.